HOPE Therapeutics and NRx Pharmaceuticals to Host Exclusive Investor Event at Mar-A-Lago Club

Upcoming Investor Event at Mar-A-Lago Club

HOPE Therapeutics™, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), is set to host a significant investor event on May 8, 2025, at the prestigious Mar-A-Lago Club in Palm Beach, Florida. This gathering aims to engage with existing investors and stakeholders, providing insights into the progress and strategic direction of both companies.

Event Overview

The exclusive invitation event will focus on previously disclosed strategic initiatives of HOPE and NRx Pharmaceuticals. Participants will gain firsthand knowledge regarding HOPE's expansion plans for its interventional psychiatry clinic network and updates on NRx's clinical pipeline.

Key Discussion Points

1. Clinic Acquisitions: The meeting will delve into recent acquisitions of HOPE clinics, exploring the potential these ventures hold for scaling their interventional psychiatry network.
2. Digital Health Integration: Attendees can expect in-depth discussions about plans to roll out digital health solutions, which involve CRM-based technology and telepsychiatry capabilities. This integration aims to create a unified clinical operation throughout the HOPE network, ultimately enhancing patient care.
3. Regulatory Updates: The status of the New Drug Application (NDA) for NRX-100, a preservative-free IV Ketamine treatment approved by the FDA with a filing fee waiver of $4.3 million, will be highlighted. This treatment specifically addresses suicidal depression, marking a significant step in mental health therapy.
4. Patent Developments: The event will also cover the recent filing of a patent for NRX-100, which, if granted, could extend market exclusivity until 2045, providing a competitive edge in the mental health pharmacotherapy sector.
5. Breakthrough Therapy Designation: A pivotal moment will be the discussion on NRX-101, which has received Breakthrough Therapy Designation, and the preparation processes for submitting an NDA for Accelerated Approval in treating bipolar depression and associated conditions.

Leadership Insights

Dr. Jonathan Javitt, MD, MPH, Founder, Chairman, and CEO of NRx Pharmaceuticals, and Co-CEO of HOPE Therapeutics, will lead this informative session. Dr. Javitt expressed enthusiasm about the investor engagement, stating, "We are excited to continue to meet with our investor community to discuss the significant progress we've made recently. Our ongoing commitment to expanding access to innovative treatments and meeting key regulatory and operational milestones underlines HOPE and NRx’s leadership in mental health innovation."

About NRx Pharmaceuticals

NRx Pharmaceuticals, known for advancing clinical-stage biopharmaceuticals, focuses on developing therapies derived from its NMDA platform for treating central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. The company holds firm plans to file an NDA for NRX-101, an investigational Breakthrough Therapy, making strides toward addressing treatment-resistant conditions with remarkable potential.

About HOPE Therapeutics

HOPE Therapeutics, as a subsidiary of NRx Pharmaceuticals, is innovatively crafting a premier network of interventional psychiatry clinics. Their goal is to elevate treatment accessibility for patients suffering from suicidal depression and related disorders by offering cutting-edge therapies like ketamine and transcranial magnetic stimulation (TMS). Additionally, they are developing a digital therapeutic-enabled platform designed to enhance the benefits of NMDA-targeted drug therapy.

Looking Ahead

As the date nears, both companies anticipate fruitful discussions that could influence future strategies and build stronger relationships within the investor community. For current investors interested in attending this pivotal event, they are encouraged to reach out directly to the company for further details and arrangements.

This investor event at Mar-A-Lago represents a significant opportunity for stakeholders to learn more about the evolving landscape of psychiatric treatments and the innovative steps HOPE and NRx are taking to address pressing mental health needs.